Diseases Studied

The Rare Diseases Clinical Research Network is an NIH-funded research network of 20 active consortia or research groups working to advance treatment for diseases that are rare. Use the search tools on this page to find the diseases we currently study. You can reach out to the indicated consortia or research groups for more information on those diseases and studies underway.

This network focuses on clinical research and does not generally support clinical care outside of research activities. To learn about other rare diseases, please visit the Genetic and Rare Diseases Information Center (GARD), which is an NIH program that helps the public find reliable information about rare and genetic diseases. Their staff are specialists. Contact them at 1-888-205-2311 or email GARDinfo@nih.gov.

All Diseases > ALG12-congenital disorder of glycosylation

ALG12-congenital disorder of glycosylation (ALG12-CDG)

Alternative Names: Congenital Disorder of Glycosylation Type Ig (CDG-1G or CDG1G)

Disease Category: Congenital Disorders of Glycosylation

A rare, inherited condition caused by a dysfunctional enzyme that cannot add mannose to proteins or fats. Symptoms manifest during infancy or early childhood, including failure to thrive, decreased muscle tone, developmental delay, intellectual disability, seizures, skeletal abnormalities, unusual facial features, sensorineural hearing loss (hearing loss caused by damage to the inner ear or the nerve from the ear to the brain), and heart muscle weakness.

Research groups studying this disease

Congenital Disorders of Glycosylation

Frontiers in Congenital Disorders of Glycosylation (FCDGC)

Learn More from the Consortium

Learn More from GARD

Recruiting

8401: Clinical and Basic Investigations into Congenital Disorders of Glycosylation

The investigators are conducting a natural history study of patients with congenital disorders of glycosylation (CDG). The study will look into the progression of the disease amongst the participants and also look at the clinical symptoms and how they vary amongst different diseased population groups. The participants will be asked to fill out questionnaires either on their own or with a provider that will grade the severity of disease and document symptoms and diet. Participants will have an opportunity to submit blood, urine, and stool samples that will be tested for biomarkers for CDG. Participants will also complete dietary food records, physical exams, CDG scores, and the PROMIS questionnaires to assess disease progression and severity.